NCT07446465 2026-03-03
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Fudan University
Phase 4 Not yet recruiting
Fudan University
Gruppo Oncologico del Nord-Ovest
University of Chicago
Amphia Hospital
Asan Medical Center
Hoffmann-La Roche
China Meitan General Hospital
Sinphar Pharmaceutical Co., Ltd